Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPIVACAINE HYDROCHLORIDE vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.
Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.
Local or regional anesthesia for surgical procedures,Dental anesthesia,Obstetric anesthesia (epidural),Postoperative pain management,Off-label: peripheral nerve blocks, sympathetic nerve blocks
Local anesthesia for dental procedures requiring infiltration or nerve block anesthesia
0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 m L for surgical anesthesia.
For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).
Terminal elimination half-life: 2.7 hours (adults); prolonged in neonates (8.1 hours) and patients with hepatic impairment; clinical context: half-life increases with repeated dosing due to accumulation.
Articaine: approximately 1-2 hours (terminal half-life). Levonordefrin: not separately reported; vasoconstrictor effect duration supports anesthetic action. Clinical context: half-life is short, reflecting rapid metabolism by plasma esterases; clinical duration of anesthesia is prolonged by levonordefrin.
Primarily hepatic via conjugation with glucuronic acid; CYP3A4 and CYP1A2 involved in metabolism to pipecoloxylidine and desbutylbupivacaine.
Articaine is metabolized primarily by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid; levonordefrin is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Primarily hepatic metabolism (CYP3A4, CYP1A2, and amidases) to pipecoloxylidine and desbutylbupivacaine; less than 5% excreted unchanged in urine; negligible biliary/fecal excretion.
Renal: primarily as metabolites (hydroxy derivatives) and unchanged drug; approximately 90% eliminated in urine as metabolites, <5% unchanged. Biliary/fecal: minor, <10%.
Approximately 95% bound to alpha-1-acid glycoprotein (AAG) and albumin; binding is concentration-dependent and decreases in acidosis.
Articaine: approximately 70-80% bound, primarily to albumin. Levonordefrin: not reported.
Vd: 0.73 L/kg (range 0.5-1.0 L/kg) in adults; reflects extensive tissue binding; lower in neonates (0.3-0.6 L/kg) due to reduced adipose tissue.
Articaine: Vd ~1.0 L/kg. Clinical meaning: moderate distribution into total body water, consistent with local anesthetic profile.
Not applicable for intravenous use; epidural: ~100% (systemic absorption from epidural space); peripheral nerve block: variable (systemic absorption depends on site and dose); oral: negligible (<5%) due to extensive first-pass metabolism.
Not applicable for local anesthetic; administered parenterally (infiltration/block). By submucosal injection:100% systemically available (though redistributes locally).
No specific dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: use with caution, reduce dose by 25% and monitor for toxicity. For GFR <10 m L/min: avoid or reduce dose by 50% with close monitoring.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: contraindicated or use minimal effective dose with extreme caution.
Child-Pugh A: No adjustment. Child-Pugh B: Consider 50% dose reduction. Child-Pugh C: Avoid use or reduce dose by 75%; monitor for systemic toxicity.
Infants and children: 0.25-0.5% solution, maximum 2 mg/kg (without epinephrine) or 3 mg/kg (with epinephrine), not to exceed 175 mg total.
Weight-based: 0.5-1.0 mg/kg per injection site, not to exceed 3.5 mg/kg total; maximum single dose 200 mg. Adjust for age and body weight; use lower concentrations (1:100,000 epinephrine equivalent).
Elderly patients: reduce dose by 25-50% due to decreased clearance and increased sensitivity; consider lower concentrations and volumes; avoid rapid infusion.
Reduce dose by 20-50% due to increased risk of cardiovascular and central nervous system effects; consider lower concentration and slower administration.
Risk of cardiac arrest and death following unintended intravenous injection or administration of high doses; resuscitation may be difficult and prolonged.
None
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Avoid for spinal anesthesia when high doses are needed due to neurotoxicity risk,Monitor for signs of CNS and cardiovascular toxicity,Use in pregnant women only if clearly needed (Category C)
Risk of methemoglobinemia, especially with higher doses, in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or exposure to oxidizing agents,Cardiovascular effects due to levonordefrin, including hypertension, hypotension, tachycardia, and cardiac arrhythmias; use caution in patients with cardiovascular disease, hypertension, or hyperthyroidism,Allergic reactions including anaphylaxis have been reported,Systemic toxicity due to inadvertent intravascular injection; observe proper injection technique,Use caution in patients with impaired liver function or severe renal impairment
Hypersensitivity to bupivacaine or other amide anesthetics,Severe hypotension (e.g., hypovolemic shock),Inflammation or sepsis at injection site,Paracervical block in obstetrics (associated with fetal bradycardia),Use for intravenous regional anesthesia (Bier block)
Hypersensitivity to articaine, levonordefrin, or any component of the formulation,Hypersensitivity to amide-type local anesthetics or sympathomimetic amines,Severe or uncontrolled hypertension,Concurrent use of MAO inhibitors or within 14 days of discontinuation (due to risk of hypertensive crisis)
No known food interactions. Grapefruit juice may affect hepatic metabolism via CYP3A4 inhibition, but clinical significance is minimal. Maintain normal diet.
No significant food interactions. Avoid alcohol consumption for at least 24 hours after the procedure as it may increase the risk of bleeding at the injection site.
Bupivacaine is classified as FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies have shown potential for fetal toxicity at high doses. Second and third trimesters: risk of fetal bradycardia and acidosis due to placental transfer. Epidural use may cause maternal hypotension reducing uteroplacental perfusion. Avoid paracervical block in pregnancy due to risk of fetal bradycardia.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause uteroplacental vasoconstriction and fetal hypoxia; avoid use during labor due to risk of maternal hypertension and fetal bradycardia.
Bupivacaine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.30. It is considered compatible with breastfeeding; however, monitor infant for signs of local anesthetic toxicity such as drowsiness or irritability.
Minimal excretion into breast milk; M/P ratio unknown. Levonordefrin has low oral bioavailability. Considered compatible with breastfeeding; monitor infant for irritability or tachycardia. Avoid application to nipples.
Increased plasma volume and decreased plasma protein binding in pregnancy may require reduced doses to avoid toxicity. However, standard epidural doses often remain similar; dose adjustment should be based on clinical response and weight. Use lower doses for combined spinal-epidural. Maximum single epidural dose: 2.5 mg/kg (non-pregnant), but in pregnancy consider 2.0 mg/kg due to increased sensitivity.
No standard dose adjustment required. Use lowest effective dose and shortest duration. Increased plasma volume in pregnancy may slightly reduce peak concentrations, but no dose adjustment is routinely recommended. Avoid use in preeclampsia or severe hypertension.
Bupivacaine is a long-acting amide local anesthetic. Maximum single dose is 2.5 mg/kg (with epinephrine 3 mg/kg). Cardiotoxicity is greater than lidocaine; avoid intravascular injection. Use with caution in hepatic impairment. For labor analgesia, 0.0625-0.125% with fentanyl is common. Adding epinephrine prolongs duration and reduces peak plasma concentration.
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a dental anesthetic containing articaine HCl 4% with epinephrine 1:100,000. Levonordefrin is a vasoconstrictor added to prolong local anesthesia. Avoid use in patients with sulfite sensitivity (articaine contains sodium metabisulfite). Maximum dose: 7 mg/kg (articaine) and not to exceed 0.5 mg levonordefrin per appointment. Do not inject into inflamed or infected tissues due to increased absorption. Aspirate before injection to prevent intravascular administration.
Report any numbness or tingling beyond expected area of anesthesia.,Seek immediate medical attention if you experience ringing in ears, metallic taste, dizziness, or seizures.,Inform your healthcare provider if you have liver disease or are taking antiarrhythmics.,Avoid driving or operating machinery until full sensation returns.,Do not apply heat or cold to the numb area to prevent burns or frostbite.
You may experience numbness in your mouth, lips, and tongue for several hours after the injection; avoid eating or drinking hot liquids until sensation returns to prevent burns.,Do not chew on the numb area to avoid accidental injury.,If you have a history of sulfite allergy, inform your dentist before the procedure.,Contact your dentist immediately if you experience severe headache, rapid heartbeat, or difficulty breathing after the injection.,This medication can cause temporary dizziness or lightheadedness; avoid driving until the effects have worn off.
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"The coadministration of bupivacaine, a sodium channel blocker used for local anesthesia, with diclofenamide, a carbonic anhydrase inhibitor and diuretic, may lead to metabolic acidosis and altered electrolyte balance, thereby increasing the risk of bupivacaine-induced cardiotoxicity and central nervous system (CNS) toxicity. Diclofenamide can cause hypokalemia and hypocalcemia, which potentiate the sodium channel blocking effects of bupivacaine, resulting in arrhythmias, seizures, or other adverse effects. This interaction is clinically significant especially in patients with renal impairment or those on multiple electrolyte-altering medications."
"Oxymorphone, a potent mu-opioid receptor agonist, and bupivacaine, a local anesthetic that blocks sodium channels, both depress the central nervous system (CNS) and respiratory drive. Coadministration may lead to additive CNS and respiratory depression, increasing the risk of severe adverse effects such as hypotension, bradycardia, and respiratory arrest. Clinical outcomes include enhanced sedation, confusion, and possibly fatal respiratory compromise, especially in patients with compromised cardiovascular function or those receiving high doses of either agent."
"Levonordefrin, a vasoconstrictor with beta-agonist activity, may counteract the beta-blocking effects of pindolol, leading to unopposed alpha-adrenergic stimulation and potential hypertensive crisis. Additionally, pindolol's intrinsic sympathomimetic activity (ISA) may interact with levonordefrin, increasing the risk of cardiac arrhythmias and AV block due to conflicting adrenergic signaling. Clinically, this can result in severe hypertension, bradycardia, or heart block, especially in patients with underlying cardiovascular disease."
"Mianserin, a tetracyclic antidepressant with potent alpha-2-adrenergic receptor antagonism, can reduce the vasopressor response to Levonordefrin, a direct-acting alpha-1 adrenergic agonist. This interaction occurs because Mianserin blocks presynaptic alpha-2 receptors, leading to increased norepinephrine release and potential receptor desensitization, as well as possible competitive antagonism at the alpha-1 receptor. Clinically, this may result in diminished efficacy of Levonordefrin when used as a local vasoconstrictor during dental or surgical procedures, potentially leading to inadequate hemostasis or reduced local anesthesia duration."
"Levonordefrin, a sympathomimetic amine with alpha- and beta-adrenergic agonist activity, can enhance the negative dromotropic effect of arotinolol, a non-selective beta-blocker with intrinsic sympathomimetic activity. This results in additive depression of atrioventricular (AV) nodal conduction, potentially leading to prolonged PR interval, second- or third-degree AV block, and symptomatic bradycardia. Clinically, patients may present with dizziness, syncope, or hemodynamic instability, particularly in those with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPIVACAINE HYDROCHLORIDE vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN, answered by our medical review team.
BUPIVACAINE HYDROCHLORIDE is a Local Anesthetic that works by Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.. ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPIVACAINE HYDROCHLORIDE and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPIVACAINE HYDROCHLORIDE is: 0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 m L for surgical anesthesia.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPIVACAINE HYDROCHLORIDE and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPIVACAINE HYDROCHLORIDE is classified as Category C. Bupivacaine is classified as FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies have shown potential for fetal toxicity at high doses. Second . ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.